YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
YIHCF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $1,269 | $2,455 | $3,086 | $3,209 |
| % Growth | -48.3% | -20.4% | -3.8% | – |
| Cost of Goods Sold | $424 | $506 | $664 | $645 |
| Gross Profit | $845 | $1,949 | $2,422 | $2,564 |
| % Margin | 66.6% | 79.4% | 78.5% | 79.9% |
| R&D Expenses | $228 | $266 | $94 | $98 |
| G&A Expenses | $192 | $194 | $214 | $172 |
| SG&A Expenses | $661 | $879 | $1,012 | $927 |
| Sales & Mktg Exp. | $493 | $661 | $792 | $756 |
| Other Operating Expenses | $150 | -$63 | $360 | $0 |
| Operating Expenses | $1,038 | $1,082 | $1,466 | $1,200 |
| Operating Income | -$193 | $867 | $956 | $1,484 |
| % Margin | -15.2% | 35.3% | 31% | 46.3% |
| Other Income/Exp. Net | -$43 | -$54 | -$91 | -$136 |
| Pre-Tax Income | -$236 | $814 | $865 | $1,262 |
| Tax Expense | -$34 | $129 | $33 | $238 |
| Net Income | -$202 | $685 | $963 | $1,029 |
| % Margin | -15.9% | 27.9% | 31.2% | 32.1% |
| EPS | -0.23 | 0.78 | 1.09 | 1.17 |
| % Growth | -129.5% | -28.4% | -6.8% | – |
| EPS Diluted | -0.23 | 0.78 | 1.09 | 1.17 |
| Weighted Avg Shares Out | 880 | 880 | 884 | 880 |
| Weighted Avg Shares Out Dil | 880 | 880 | 880 | 880 |
| Supplemental Information | – | – | – | – |
| Interest Income | $70 | $0 | $63 | $102 |
| Interest Expense | $98 | $0 | $0 | $0 |
| Depreciation & Amortization | -$7,793 | $8,189 | $194 | $189 |
| EBITDA | -$7,936 | $9,007 | $1,499 | $1,660 |
| % Margin | -625.4% | 366.9% | 48.6% | 51.7% |